Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“Bladder cancer editorial commentary on ReachMD – tumor-informed circulating-tumor (ct)-DNA following radical cystectomy for high-risk muscle-invasive bladder cancer- IMvigor011 Phase III trial showed that 1) ctDNA-guided adjuvant atezolizumab extended disease-free survival and overall survival and 2) persistent ctDNA-negative status exhibited excellent outcomes.
The applicability of these data to the era of perioperative EV + pembrolizumab and gemcitabine-cisplatin-durvalumab is being evaluated in the MODERN clinical trial (NCT05987241) – pleased to share my comments in this discussion from Adventhealth Cancer Institute AdventHealth Central Florida Orlando, Florida.”
Other articles about Bladder Cancer on OncoDaily.